5402222026-04-012026-06-305402222026-04-012026-06-30in-capmkt:OtherExpenses1Member5402222026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15402222026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2026-04-012027-03-312026-07-242026-07-09INRCroresQuarterlyFirst quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2026-07-2414:00:002026-07-2414:42:00Not applicable2026-04-012026-06-30UnauditedConsolidated2026310000091800000203549000007857700000351200000-648800000258700000042220000012387000003733300000155413000004813600000048136000001348800000-1551000001193700000036199000000008000003620700000-2210000035986000003676000000-553000003653900000-55300000108050000026.816.8006.816.81.The above consolidated unaudited financial results of Laurus Labs Limited including its subsidiaries and its associates and joint venture as mentioned in note 3 has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 24 2026. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30 2026 <br /> 2.These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. <br /> 3.The consolidated financial results include the results of the following entities <br /> Please see the table from the filed results pdf <br /> 4.a The Company incorporated wholly owned subsidiary Laurus Specialty Chemicals Private Limited iin India on December 01 2022. LSCPL has not commenced its operations. <br /> 4.b During the quarter ended December 31 2025 the company has invested INR 35 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited Eight Roads Ventures and F Prime Capital. <br /> 4.c Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited Capital contribution of INR 49 Crores have been made into KRKA in terms of the aforesaid agreement during the quarter ended December 31 2025 for 49 percent stake. The Company has accounted for the investment in KRKA as joint venture. <br /> 5.Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter ended June 30 2025 . The Company has accounted for its investment in Kurnool Renewables as an associate wef May 12 2025. <br /> 6.The Group is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments <br /> 7.The Board of Directors of the Company in its meeting held on August 21 2025 approved the proposed Composite Scheme of Arrangement for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company subject to the necessary approval from National Company Law Tribunal Amaravathi under section 230 and 232 of the Companies Act 2013 and other applicable provisions of the Act and the rules made thereunder. The Company have filed the Scheme with the Honble National Company Law Tribunal Amaravati Bench at Amaravati Andhra Pradesh and accordingly the implementation of the Scheme is subject to the final approvals and sanctions of the applicable authorities. Upon approval of the Scheme Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01 2026 or such other date as the NCLT may approve. Pending such approval the consolidated financial results of the Company are presented without giving effect to the said merger. <br /> 8.During the quarter ended June 30 2026 the Company allotted 393001 equity shares of INR 2 each consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <br /> 9.The figures for the quarter ended March 31 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31 2026 and published year to date figures up to third quarter of the financial year ended March 31 2026 which were subject to limited review by the statutory auditors.Other Expenses3733300000i. Remeasurement gains/(losses) on defined benefit plans-24200000-24200000-6100000Exchange differences on translating the financial statements of foreign operations-4000000-40000000-22100000